Momenta Pharmaceuticals, Inc. (MNTA) Appoints Michael Franken, M.D. as President, Biosimilars Business
12/12/2013 9:38:49 AM
CAMBRIDGE, Mass., Dec. 12, 2013 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA) announced today that it has named Michael Franken, M.D. as President, Biosimilars Business. Dr. Franken will oversee the operational management of Momenta's biosimilars program, including its collaboration with Baxter International Inc., strategic planning, P&L responsibility, and other supporting activities. Dr. Franken will report to Craig Wheeler, Momenta's President and Chief Executive Officer, and will serve as a member of the Executive Committee.
Help employers find you! Check out all the jobs and post your resume.
comments powered by